Sage Journals: Discover world-class research

Abstract

Introduction:

Guselkumab is an Interleukin-23 inhibitor that has been shown to be effective for the treatment of psoriasis even in patients with an inadequate response to ustekinumab. At this time, there are no published reports of worsening psoriasis or psoriatic arthritis on guselkumab compared to ustekinumab.

Methods:

We reviewed the charts of two patients with psoriasis who were treated in our clinic with guselkumab after failing treatment with ustekinumab.

Results:

The patient in case 1 experienced a psoriasis flare after switching from ustekinumab to guselkumab. The patient in case 2 has an increase in body surface area of her psoriasis as well as worsening joint symptoms while on guselkumab compared to ustekinumab.

Discussion:

Not all patients will have a superior response to guselkumab than ustekinumab.

Keywords

psoriasis psoriatic arthritis case report ustekinumab interleukin 12/23 inhibitor biologic treatment interleukin 23 inhibitor guselkumab

Get full access to this article

View all access options for this article.

References

Puig

. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–534. doi:10.1080/1744666X.2017.1292137.

Deodhar

Gottlieb

Boehncke

W-H

. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet (London, England). 2018;391(10136):2213–2224. doi:10.1016/S0140-6736(18)30952-8.

Langley

Tsai

Flavin

. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. doi:10.1111/bjd.15750.

Boutet

Nerviani

Gallo Afflitto

Pitzalis

. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530. doi:10.3390/ijms19020530.

Brito-Luna

Villanueva-Quintero

Sandoval-Talamantes

. Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report. Cytokine. 2016;85:130–136. doi:10.1016/j.cyto.2016.06.020.

Croxford

Kulig

Becher

. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev. 2014;25(4):415–421. doi:10.1016/j.cytogfr.2014.07.017.

Two Cases of Worsening Psoriasis After Switching From Ustekinumab to Guselkumab